Gilead Agrees to Buy PepStar Oral IL-23 Receptor Program

Company Gilead Sciences; PepStar Therapeutics Event Type Program acquisition (source-gap reconciliation) Modality Oral macrocyclic peptide Asset HCXT-2001 Target IL-23 receptor Disease Area Inflammatory bowel disease; psoriasis Summary Source-gap reconciliation: Gilead’s 22 October 2026 agreement to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program was absent…